Funding round completed
Miracor GmbH of Vienna has raised €6 million in its first round funding, to develop a PICSO (Pressure-controlled Intermittent Coronary Sinus Occlusion) medical device for use in patients being treated for heart attacks or in heart failure. The round was led by Earlybird and Delta Partners.
Miracor says that of the 59 million people worldwide who suffer from heart disease, more than 20 per cent could benefit from PICSO therapy.
The company was founded by Werner Mohl, a cardiac surgeon at the Medical University of Vienna.
Commenting on the investment, Earlybird Partner, Thom Rasche said, “This therapeutic approach has the potential to help millions of patients. We look forward to supporting the management team in building the company and launching the technology with clinical opinion leaders globally. We are very pleased to make this investment as it is an ideal fit with our investment criteria where a prototype has been developed and the technology is clinically validated.”
Receive the Funding Newswire [full access requires a subscription] each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening. 
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.
